Hypothesis

Senescent cells sequester circulating cytokines through high expression of decoy receptors and soluble cytokine-binding proteins, thereby dampening the magnitude of acute inflammatory signals. Senolytic ablation eliminates this buffering capacity, leading to exaggerated JAK-STAT activation upon subsequent immune challenge.

Mechanistic Basis

• Senescent cells upregulate a repertoire of soluble receptors (e.g., sIL-6Rα, sTNFR1, sIL-1RII) as part of the SASP, a feature documented in early‑senescence phases that promote tissue remodeling [4].
• These decoy molecules bind cytokines with high affinity, reducing free ligand concentrations available to activate membrane-bound receptors on neighboring cells.
• Chronic exposure to senescent cell‑derived SASP also induces baseline JAK-STAT phosphorylation in immune cells [3]; however, the acute‑phase response depends on the dynamic balance between free cytokine and its soluble antagonists.
• Removal of senescent cells shifts this balance toward increased free cytokine, producing a transient hyper‑responsive state that we term “cytokine sink loss” (CSL).

Testable Predictions

1. Biomarker shift: After senolytic treatment, plasma levels of free IL-6, TNF‑α, and IL‑1β will rise significantly following a standardized LPS challenge, while total cytokine levels remain unchanged.
2. Receptor occupancy: Soluble receptor concentrations (sIL-6Rα, sTNFR1) will decrease proportionally to the reduction in senescent cell burden, measurable by ELISA.
3. Functional readout: Mice treated with senolytics will exhibit heightened STAT1/STAT3 phosphorylation in splenic macrophages 30 min post‑LPS, accompanied by exaggerated NF‑κB‑driven gene expression (e.g., Nos2, Il12b).
4. Rescue experiment: Administration of recombinant soluble cytokine receptors to senolytic‑treated animals will normalize the exaggerated JAK-STAT response without affecting senescent cell numbers.

Experimental Design

• Model: Use aged (20‑month) C57BL/6 mice; administer dasatinib + quercetin (D+Q) or vehicle twice weekly for three doses to achieve senolytic clearance [2].
• Senolysis verification: Quantify p16^Ink4a^‑positive cells via immunohistochemistry and flow cytometry in liver, lung, and spleen.
• Cytokine sink assay: Collect plasma at baseline, 6 h, and 24 h after intraperitoneal LPS (5 µg/g). Measure total cytokine (Luminex) and free cytokine (after immunodepletion of soluble receptors).
• Signaling readout: Isolate splenic macrophages at 30 min post‑LPS; assess pSTAT1/STAT3 by phospho‑flow and downstream transcripts by qPCR.
• Rescue arm: In a subset, inject recombinant sIL-6Rα (1 µg/g) 1 h before LPS; repeat signaling and cytokine measurements.
• Controls: Include young (3‑month) mice receiving D+Q to control for off‑target drug effects.

Interpretation

If senolytics increase free cytokine levels and amplify JAK-STAT signaling after an acute stimulus, the data will support the notion that senescent cells function as a cytokine sink that restrains inflammation. Conversely, absence of such changes would refute the CSL mechanism and suggest that any protective role of senescent cells operates via alternative pathways (e.g., matrix remodeling, metabolic support).

Broader Implications

Confirming a cytokine‑sink role would necessitate revisiting senolytic dosing regimens—potentially coupling transient senolysis with timed supplementation of soluble receptor mimetics to preserve acute immune competence while alleviating chronic inflammaging. It also provides a mechanistic explanation for observed “signal exhaustion” in aging: persistent senescent cell burden may chronically sequester cytokines, blunting fold‑change responses upon new insults.

This hypothesis is directly falsifiable, relies on measurable biochemical readouts, and extends the current SASP paradigm by proposing a specific, tractable molecular function for senescent cells in immune homeostasis.